Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27556760
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Plast+Reconstr+Surg
2016 ; 138
(3 Suppl
): 18S-28S
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Biology and Biomarkers for Wound Healing
#MMPMID27556760
Lindley LE
; Stojadinovic O
; Pastar I
; Tomic-Canic M
Plast Reconstr Surg
2016[Sep]; 138
(3 Suppl
): 18S-28S
PMID27556760
show ga
BACKGROUND: As the population grows older, the incidence and prevalence of
conditions that lead to a predisposition for poor wound healing also increase.
Ultimately, this increase in nonhealing wounds has led to significant morbidity
and mortality with subsequent huge economic ramifications. Therefore,
understanding specific molecular mechanisms underlying aberrant wound healing is
of great importance. It has and will continue to be the leading pathway to the
discovery of therapeutic targets, as well as diagnostic molecular biomarkers.
Biomarkers may help identify and stratify subsets of nonhealing patients for whom
biomarker-guided approaches may aid in healing. METHODS: A series of literature
searches were performed using Medline, PubMed, Cochrane Library, and Internet
searches. RESULTS: Currently, biomarkers are being identified using biomaterials
sourced locally from human wounds and/or systemically using high-throughput
"omics" modalities (genomic, proteomic, lipidomic, and metabolomic analysis). In
this review, we highlight the current status of clinically applicable biomarkers
and propose multiple steps in validation and implementation spectrum, including
those measured in tissue specimens, for example, ?-catenin and c-myc, wound
fluid, matrix metalloproteinases and interleukins, swabs, wound microbiota, and
serum, for example, procalcitonin and matrix metalloproteinases. CONCLUSIONS:
Identification of numerous potential biomarkers using different avenues of sample
collection and molecular approaches is currently underway. A focus on simplicity
and consistent implementation of these biomarkers, as well as an emphasis on
efficacious follow-up therapeutics, is necessary for transition of this
technology to clinically feasible point-of-care applications.
|Biomarkers/*metabolism
[MESH]
|Chronic Disease
[MESH]
|Humans
[MESH]
|Plastic Surgery Procedures
[MESH]
|Postoperative Complications/*diagnosis/metabolism/microbiology/prevention &
control
[MESH]
free
free
free
